Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From the Randomized, Placebo-Controlled, Phase III INVIGORATE-1 Study
Arthritis Rheumatol. 2024 Sep 19 doi 10.1002/art.42993 Epub ahead of print
Deodhar et al. evaluated the efficacy and safety of intravenous secukinumab in patients with active axial spondyloarthritis. The study found a significant improvement in the ASAS40 response at Week 16 (40.9% vs 22.9% in placebo, P<0.0001), with responses maintained through Week 52. No new safety signals were observed.
The phase III INVIGORATE-1 study was a randomized, placebo-controlled trial enrolling 526 patients with axial spondyloarthritis. Patients were treated with either intravenous secukinumab or placebo for 16 weeks, with a primary outcome measured at Week 16 and safety monitored through Week 60.
Keywords:
